Skip to content
Blerp – Lifestyle
Author:
Vittoria Biotherapeutics
Vittoria Biotherapeutics to Present Phase 1 Results for Senza5 CART5 in T-Cell Lymphoma in an Oral Session and LampTAC Degrader Platform Data in a Poster Session at ASH 2026
November 17, 2026
Vittoria Biotherapeutics Announces FDA RMAT and Orphan Drug Designations for Senza5 CART5 (VIPER-101) in T-Cell Lymphoma
November 10, 2026